Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Gan To Kagaku Ryoho ; 48(13): 2106-2108, 2021 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-35045507

RESUMEN

A 51-year-old male presented with dyspnea due to upper airway obstruction. We decided to perform a cricothyroidotomy due to difficulty in performing orotracheal intubation. A CT scan revealed a massive tumor infiltrating into the right side of the neck, which penetrated the internal carotid artery. An upper gastrointestinal tract endoscopy was performed, and the patient was diagnosed with advanced esophageal cancer(stage Ⅳ, cT4N4M0). We initiated palliative chemotherapy of FOLFOX as first-line chemotherapy. After the fourth course, the patient was evaluated as having progressive disease(PD)due to regrowth of lymph node metastasis around the lower esophagus. Although we changed the treatment to nivolumab as second-line chemotherapy, there was a gradual exacerbation of airway obstruction, and the head and upper limb edema emerged due to superior vena cava syndrome. After the first course of nivolumab, we diagnosed the patient as having clinically PD. After the first course of docetaxel(DTX)as third-line chemotherapy, he suddenly died of massive hemorrhage caused by the intubation tube on day 136. Airway management is difficult to perform in patients with a poor response to chemotherapy due to obstruction by a tumor. On the other hand, excessive response to chemotherapy is also associated with a risk of massive hemorrhage due to arterial perforation, as observed in this case.


Asunto(s)
Neoplasias Esofágicas , Síndrome de la Vena Cava Superior , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Asfixia , Arteria Carótida Interna , Neoplasias Esofágicas/complicaciones , Neoplasias Esofágicas/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Tráquea
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...